Holen Sie sich die Stockscreener-App
4.98
1.39%
-0.07
Schlusskurs vom Vortag:
$5.05
Offen:
$4.92
24-Stunden-Volumen:
5,884
Relative Volume:
0.52
Marktkapitalisierung:
$57.21M
Einnahmen:
$800.00K
Nettoeinkommen (Verlust:
$-45.07M
KGV:
-0.9471
EPS:
-5.2583
Netto-Cashflow:
$-52.08M
1W Leistung:
+0.40%
1M Leistung:
-12.48%
6M Leistung:
-15.88%
1J Leistung:
-45.81%
1-Tages-Spanne:
$4.865
$5.14
1-Wochen-Bereich:
$4.73
$5.285
52-Wochen-Spanne:
$3.94
$9.22
Imagenebio Inc Stock (IMA) Company Profile
Firmenname
Imagenebio Inc
Sektor
Branche
Telefon
857-343-8292
Adresse
12526 HIGH BLUFF DRIVE, SAN DIEGO
Compare IMA vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMA
Imagenebio Inc
|
5.04 | 57.32M | 800.00K | -45.07M | -52.08M | -5.2583 |
VRTX
Vertex Pharmaceuticals Inc
|
522.11 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.76 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,004.25 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.30 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.67 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Imagenebio Inc Stock (IMA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-25 | Fortgesetzt | Wedbush | Underperform |
| 2025-10-24 | Eingeleitet | Leerink Partners | Outperform |
Imagenebio Inc Aktie (IMA) Neueste Nachrichten
ImageneBio to Participate in H.C. Wainwright 28th Annual Global Investment Conference in New York - The Manila Times
A biotech CEO will speak in New York. ImageneBio will archive the webcast for 90 days. - Stock Titan
ImageneBio, Inc. (NASDAQ: IMA) Share Price, IMA Stock News, IMA Share Price & Updates - Kalkine
IMA Q2 2026 Earnings: Narrower EPS Loss Beats Estimates, Shares Slip 6.4%Earnings Call Highlights - vinanet.vn
ImageneBio (IMA) Edges Higher to $5.34 as Bulls Defend Key SupportPost-Earnings Moves - vinanet.vn
ImageneBio (IMA) Market: Finishes 1.78% Lower at $5.51 in the Current Update; Technical View: the Price Remains Bounded by the Supplied Support and Resistance on the DayCorrective Wave - vinanet.vn
ImageneBio, Inc. (NASDAQ:IMA) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
HC Wainwright Initiates ImageneBio at Buy With $28 Price Target - marketscreener.com
Blue Owl Capital Holdings LP Invests $5.41 Million in ImageneBio, Inc. $IMA - MarketBeat
ImageneBio (NASDAQ:IMA) Trading 1.8% HigherWhat's Next? - MarketBeat
ImageneBio Reports Inducement Grants under Nasdaq Listing Rule 5635(4) - marketscreener.com
ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
ImageneBio (IMA) shifts CFO equity mix toward RSUs in new grant - Stock Titan
ImageneBio's New Hires Get Stock Awards as CFO Gets a Separate Award - Stock Titan
ImageneBio, Inc. (IMA): BVF group discloses 9.99% stake and large warrants - Stock Titan
ImageneBio, Inc. SEC Filing (Aug 12, 2026) - Stock Titan
IMA Stock Surges 24%, Breaks 50-DMA For First Time Since February – What's Driving The Rally? - Stocktwits
ImageneBio Ord Shs (IMA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ImageneBio, Inc. SEC Filing (Aug 7, 2026) - Stock Titan
Wedbush Maintains ImageneBio(IMA.US) With Sell Rating, Maintains Target Price $2 - Moomoo
William Blair Maintains ImageneBio(IMA.US) With Buy Rating - Moomoo
ImageneBio (IMA) registers 1.37M existing shares for resale on Form S-3 - Stock Titan
ImageneBio (IMA) sets up $200M shelf and $17M ATM stock program - Stock Titan
ImageneBio (IMA) files to register 5.77M warrant shares for investor resale - Stock Titan
ImageneBio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
ImageneBio Inc reports results for the quarter ended June 30Earnings Summary - TradingView
ImageneBio Sees Cash Runway Funding Planned Ops Into 1Q of 2028 >IMA - Moomoo
ImageneBio, Inc. Q2 2026: Revenue $0 EPS $(0.63) — 10-Q Summary - TradingView
ImageneBio Reports Second Quarter 2026 Financial Results - The Manila Times
ImageneBio Reports Second Quarter 2026 Financial Results and Corporate Update on Olevaprubart Clinical Development - Quiver Quantitative
ImageneBio reports Q2 2026: $136.2M cash; $10.2M net loss for quarter - TradingView
ImageneBio Posts $10.2 Million Q2 Loss With Cash Runway Into 2028 - Quiver Quantitative
ImageneBio (Nasdaq: IMA) details Q2 2026 loss and $136M cash runway - Stock Titan
IMA: Clinical pipeline advances and robust cash position support continued development through 2028 - TradingView
ImageneBio’s Atopic Dermatitis Data Anticipated in Q4 2027 - Stock Titan
IKNA Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
IMA Q2'26 Earnings: revenue estimate is 0 USD - TradingView
ImageneBio, Inc. Revenue Breakdown – NASDAQ:IMA - TradingView
ImageneBio Inc. (IMA) Q1 2026 Earnings: EPS Miss Highlights Pre‑Revenue Challenges as Stock Rises - dars.gov.et
ImageneBio (NASDAQ:IMA) Trading Up 2.9%Should You Buy? - MarketBeat
ImageneBio Ord Shs (IMA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
IMA|ImageneBio Ord Shs|Price:5.600| - TradingKey
ImageneBio, Inc. Revenue Breakdown – BOATS:IMA - TradingView
ImageneBio Inc. (IMA) Q1 2026 Earnings: EPS Misses Estimates Amid Continued R&D InvestmentTax Rate Impact - vinanet.vn
ImageneBio Inc. (IMA) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
ImageneBio Strengthens Leadership with New CFO Appointment - TipRanks
ImageneBio (IMA) hires CFO with $450,000 salary and equity awards - Stock Titan
Imagenebio, Inc. Appoints Yanina Grant-Huerta as Chief Financial Officer, Effective July 20, 2026 - marketscreener.com
IMA Q1 2026 Earnings: Wider-Than-Expected Loss Reflects Continued R&D InvestmentOperating Margin Analysis - vinanet.vn
Form 4 ImageneBio Inc For: 21 July By Investing.com - Investing.com South Africa
ImageneBio principal accounting officer sells $17,334 in stock By Investing.com - Investing.com Nigeria
Finanzdaten der Imagenebio Inc-Aktie (IMA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.63%
3.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):